NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$14.89
+5.83%Year over year
Reported trailing growth
- Revenue
- +11.0%
- EBITDA
- -34.4%
- EBIT
- +10.6%
- EPS
- +16.7%
- Free cash flow
- +73.7%
- Operating cash flow
- +103.3%
Forward estimates
Based on analyst estimates
- Revenue
- +9.8%
- EBITDA
- +44.4%
- EPS
- +35.3%
Three-year CAGR
- Revenue
- +6.8%
- EBITDA
- -11.0%
- EBIT
- +9.8%
- Net income
- +19.2%
- EPS
- +21.8%
- Free cash flow
- -9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026